Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:CVRX NASDAQ:MBOT NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.48-0.4%$0.63$0.45▼$1.39$29.95M1.4382,359 shs19,441 shsCVRXCVRx$5.87-1.2%$7.75$4.37▼$11.30$155.74M0.9350,921 shs18,013 shsMBOTMicrobot Medical$1.67-6.5%$2.35$1.60▼$4.67$111.83M1.061.88 million shs874,485 shsTMCITreace Medical Concepts$2.88+4.5%$1.72$1.17▼$7.78$186.50M1.1778,222 shs176,816 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-3.74%-23.97%-27.42%-25.17%-46.78%CVRXCVRx-0.83%-14.16%-19.29%+25.32%-6.31%MBOTMicrobot Medical-3.78%-18.72%-23.93%-16.04%-33.58%TMCITreace Medical Concepts+3.38%+41.75%+41.75%+50.27%-59.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.48-0.4%$0.63$0.45▼$1.39$29.95M1.4382,359 shs19,441 shsCVRXCVRx$5.87-1.2%$7.75$4.37▼$11.30$155.74M0.9350,921 shs18,013 shsMBOTMicrobot Medical$1.67-6.5%$2.35$1.60▼$4.67$111.83M1.061.88 million shs874,485 shsTMCITreace Medical Concepts$2.88+4.5%$1.72$1.17▼$7.78$186.50M1.1778,222 shs176,816 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-3.74%-23.97%-27.42%-25.17%-46.78%CVRXCVRx-0.83%-14.16%-19.29%+25.32%-6.31%MBOTMicrobot Medical-3.78%-18.72%-23.93%-16.04%-33.58%TMCITreace Medical Concepts+3.38%+41.75%+41.75%+50.27%-59.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.381,026.83% UpsideCVRXCVRx 3.00Buy$11.5095.91% UpsideMBOTMicrobot Medical 2.60Moderate Buy$7.50350.45% UpsideTMCITreace Medical Concepts 1.86Reduce$4.7765.91% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, TMCI, CVRX, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CVRXCVRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026TMCITreace Medical Concepts Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026CVRXCVRx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/14/2026MBOTMicrobot Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/10/2026MBOTMicrobot Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026CTSOCytosorbents D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/2/2026TMCITreace Medical Concepts Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.50 ➝ $7.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.20M0.81N/AN/A$0.09 per share5.30CVRXCVRx$59.07M2.64N/AN/A$1.50 per share3.91MBOTMicrobot Medical$105K1,065.05N/AN/A$1.15 per share1.45TMCITreace Medical Concepts$212.69M0.88N/AN/A$1.37 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.19N/AN/AN/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)CVRXCVRx-$53.31M-$2.02N/AN/AN/A-89.14%-120.76%-48.38%8/4/2026 (Estimated)MBOTMicrobot Medical-$13.14M-$0.26N/AN/AN/AN/A-21.84%-20.71%N/ATMCITreace Medical Concepts-$59M-$0.97N/AN/AN/A-29.44%-67.04%-30.28%8/6/2026 (Estimated)Latest CTSO, TMCI, CVRX, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 million5/13/2026Q1 2026MBOTMicrobot Medical-$0.08-$0.05+$0.03-$0.05$0.30 million$0.11 million5/11/2026Q1 2026CVRXCVRx-$0.51-$0.50+$0.01-$0.50$14.49 million$14.77 million5/8/2026Q1 2026TMCITreace Medical Concepts-$0.31-$0.28+$0.03-$0.28$45.96 million$47.20 million3/27/2026Q4 2025MBOTMicrobot Medical-$0.06-$0.04+$0.02-$0.04$0.11 millionN/A3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 millionN/A2/27/2026Q4 2025TMCITreace Medical Concepts-$0.15-$0.15N/A-$0.15$61.76 million$62.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/ACVRXCVRxN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents4.701.090.81CVRXCVRx2.0110.208.89MBOTMicrobot Medical0.0122.5921.93TMCITreace Medical Concepts0.723.582.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%CVRXCVRx75.27%MBOTMicrobot Medical16.30%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%CVRXCVRx13.90%MBOTMicrobot Medical4.74%TMCITreace Medical Concepts23.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.80 million58.65 millionOptionableCVRXCVRx16026.54 million21.52 millionOptionableMBOTMicrobot Medical2067.17 million63.98 millionOptionableTMCITreace Medical Concepts25064.87 million49.68 millionOptionableCTSO, TMCI, CVRX, and MBOT HeadlinesRecent News About These CompaniesTreace Medical Concepts, Inc.May 15, 2026 | edition.cnn.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 43,000 SharesMay 15, 2026 | insidertrades.comTreace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 12, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...May 9, 2026 | finance.yahoo.comTreace Medical Concepts Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comTreace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings ResultsMay 8, 2026 | marketbeat.comTreace Medical Concepts: Q1 Earnings SnapshotMay 8, 2026 | myjournalcourier.comMTreace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue EstimatesMay 8, 2026 | zacks.comTreace Medical Concepts Reports First Quarter 2026 Financial ResultsMay 8, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Report Preview: What To ExpectMay 7, 2026 | finance.yahoo.comHow The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst ExpectationsMay 3, 2026 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from AnalystsMay 3, 2026 | marketbeat.comTreace Medical Concepts (TMCI) to Release Earnings on FridayMay 1, 2026 | marketbeat.comWeber Capital Management LLC ADV Invests $1.45 Million in Treace Medical Concepts, Inc. $TMCIApril 27, 2026 | marketbeat.comTreace Medical Concepts (NASDAQ:TMCI) Upgraded to Sell at Wall Street ZenApril 27, 2026 | marketbeat.comTreace Medical Concepts, Inc. to Release First Quarter 2026 Financial Results and Host Conference CallApril 24, 2026 | quiverquant.comQTreace to Report First Quarter 2026 Financial Results on May 8, 2026April 24, 2026 | globenewswire.comHow The Treace Medical Concepts (TMCI) Narrative Is Shifting With New Targets And Product PlansApril 18, 2026 | finance.yahoo.comTreace Medical Concepts Announces Leadership Transition and OutlookApril 11, 2026 | theglobeandmail.comTreace Medical Concepts (TMCI) price target increased by 12.28% to 4.08April 10, 2026 | msn.comTreace Medical Concepts, Inc.: Treace Announces First Surgical Cases with the SuperBite Compression Screw SystemApril 7, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTSO, TMCI, CVRX, and MBOT Company DescriptionsCytosorbents NASDAQ:CTSO$0.48 0.00 (-0.42%) As of 10:45 AM Eastern This is a fair market value price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.CVRx NASDAQ:CVRX$5.87 -0.07 (-1.18%) As of 10:47 AM Eastern This is a fair market value price provided by Massive. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Microbot Medical NASDAQ:MBOT$1.66 -0.12 (-6.46%) As of 10:48 AM Eastern This is a fair market value price provided by Massive. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Treace Medical Concepts NASDAQ:TMCI$2.88 +0.13 (+4.55%) As of 10:47 AM Eastern This is a fair market value price provided by Massive. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
